Pathway Genomics

From Wikipedia, the free encyclopedia
Pathway Genomics Corporation
Type Private
Industry Biotechnology
Founded 2008
Founder(s) Jim Plante
Headquarters San Diego, California
Website www.pathway.com

Pathway Genomics is a privately held personal genomics company based in San Diego, California. Using DNA genetic testing technologies, the company conducts services to generate personalized reports about an individual’s carrier status, drug (medication) response, propensity for the development of certain complex diseases, as well as ancestral history. The company provides these personal genetic reports to physicians and their patients. Pathway Genomics owns and operates a federally CLIA (Clinical Laboratory Improvement Amendments) certified and California state-licensed on-site laboratory.[1] According to its website, Pathway Genomics reports on a number of health conditions including Alzheimer's disease, type 1 and type 2 diabetes, hypertension, asthma, rheumatoid arthritis, cystic fibrosis and beta thalassaemia, as well as screens for drug responses for such medications as Plavix and warfarin (Coumadin). The company has registered its saliva collection kit with the U.S. Food and Drug Administration (FDA) as a Class I 510(K) Exempt medical device.[2]

History

Pathway Genomics was founded in 2008 by Jim Plante, an entrepreneur in the industries of technology and preventive healthcare. Mr. Plante founded four other venture capital-supported technology companies and he is responsible for launching new product lines and services in the consumer products, automotive, wireless, and risk-management service industries. Pathway Genomics’ scientific team is led by David Becker, Ph.D., Chief Scientific Officer. Dr. Becker is most notably recognized for his contribution to Alzheimer’s disease research. During his time working at Torrey Pines Therapeutics, Dr. Becker and his team worked with Rudolph Tanzi, Ph.D., of Massachusetts General Hospital and Harvard Medical School in the discovery and validation of genes that contribute to the pathogenesis of Alzheimer's disease.[3]

See also

Genetic testing
Single-nucleotide polymorphism (SNP)
Genetic carrier
Complex disease
Pharmacogenomics
Genetic counseling
Genomic counseling
Clinical Laboratory Improvement Amendments (CLIA)

References

  1. ↑ "New DTC Genetics Firm Pathway Genomics Launches." GenomeWeb Daily News. 15 July 2009. Retrieved 2010-7-16
  2. ↑ "Pathway Genomics Obtains FDA Registration." Press Release; Business Wire. 28 September 2011. Retrieved 2011-10-11
  3. ↑ Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE. "Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE." American Journal of Human Genetics. 2008 Nov;83(5):623-32.Epub 30 October 2008. (PMID 18976728)

Further reading

  • Alberg AJ, Ford JG, Samet JM; American College of Chest Physicians. “Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).” Chest. 2007 Sep;132(3 Suppl):29S-55S. (PMID 17873159)
  • Bertram L, Tanzi RE. “Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.” Nature Reviews: Neuroscience. 2008 Oct;9(10):768-78. (PMID 18802446)
  • Bu G. “Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy.” Nature Reviews: Neuroscience. 2009 May;10(5):333-44. Epub 2 April 2009. (doi:10.1038/nrn2620 PMID 19339974)
  • Carlsson C, Nilbert M. “Living with hereditary non-polyposis colorectal cancer; experiences from and impact of genetic testing.” Journal of Genetic Counseling. 2007 Dec;16(6):811-20. Epub 18 August 2007. (PMID 17705030)
  • Coyle YM. “Lifestyle, genes, and cancer.” Methods in Molecular Biology. 2009;472:25-56. (PMID 19107428)
  • Epstein RS, Moyer TP, Aubert RE, O'Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR. “Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study).” Journal of the American College of Cardiology. 7 April 2010. [Epub ahead of print] (PMID 20381283)
  • Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA. REVEAL Study Group; “Disclosure of APOE genotype for risk of Alzheimer's disease.” The New England Journal of Medicine. 2009; 361: 245–54. (PMID 19605829)
  • Heshka JT, Palleschi C, Howley H. et al. “A systematic review of perceived risks, psychological and behavioral impacts of genetic testing.” Genetics in Medicine. 2008; 10(1): 19–32. (PMID 18197053)
  • Low CA, Bower JE, Kwan L, Seldon J. “Benefit finding in response to BRCA1/2 testing.” Annals of Behavioral Medicine. 2008 Feb;35(1):61-9. Epub 15 February 2008. (PMID 18347905)
  • McBride CM, Koehly LM, Sanderson SC, Kaphingst KA. “The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behaviors?” Annual Review of Public Health. 21 April 2010;31:89-103. (PMID 20070198)
  • Rief W, Conradt M, Dierk JM, Rauh E, Schlumberger P, Hinney A, Hebebrand J. “Is information on genetic determinants of obesity helpful or harmful for obese people?--A randomized clinical trial.” Journal of General Internal Medicine. 2007 Nov;22(11):1553-9. Epub 19 September 2007. (PMID 17879121)
  • Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y. “Physical activity, diet, and risk of Alzheimer disease.” Journal of the American Medical Association. 12 August 2009;302(6):627-37. (PMID 19671904)
  • Scheuner MT, Sieverding P, Shekelle PG. “Delivery of genomic medicine for common chronic adult diseases a systematic review.” Journal of the American Medical Association. 2008;299:1320–1334. (PMID 18349093)
  • Taylor DH Jr, Cook-Deegan RM, Hiraki S, Roberts JS, Blazer DG, Green RC. “Genetic testing for Alzheimer's and long-term care insurance.” Health Affairs (Project Hope). 2010 Jan-Feb;29(1):102-8. (PMID 20048367)
  • Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. “Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.” The New England Journal of Medicine. 3 May 2001;344(18):1343-50. (doi:10.1056/NEJM200105033441801 PMID 11333990)

External links

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.